X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs DIVIS LABORATORIES - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. DIVIS LABORATORIES WOCKHARDT LTD./
DIVIS LABORATORIES
 
P/E (TTM) x -11.0 31.4 - View Chart
P/BV x 2.2 5.1 42.9% View Chart
Dividend Yield % 1.5 1.0 155.1%  

Financials

 WOCKHARDT LTD.   DIVIS LABORATORIES
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
DIVIS LABORATORIES
Mar-17
WOCKHARDT LTD./
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1291,222 92.4%   
Low Rs627784 80.0%   
Sales per share (Unadj.) Rs363.1153.1 237.2%  
Earnings per share (Unadj.) Rs-20.439.9 -51.2%  
Cash flow per share (Unadj.) Rs-7.044.6 -15.6%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.11.0 114.2%  
Book value per share (Unadj.) Rs301.8201.8 149.6%  
Shares outstanding (eoy) m110.55265.47 41.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.46.6 36.9%   
Avg P/E ratio x-42.925.1 -171.0%  
P/CF ratio (eoy) x-125.922.5 -559.6%  
Price / Book Value ratio x2.95.0 58.5%  
Dividend payout %-48.925.0 -195.4%   
Avg Mkt Cap Rs m97,063266,266 36.5%   
No. of employees `0006.89.7 69.5%   
Total wages/salary Rs m9,6654,687 206.2%   
Avg. sales/employee Rs Th5,931.84,175.0 142.1%   
Avg. wages/employee Rs Th1,428.1481.5 296.6%   
Avg. net profit/employee Rs Th-334.01,089.3 -30.7%   
INCOME DATA
Net Sales Rs m40,14640,643 98.8%  
Other income Rs m1,143749 152.6%   
Total revenues Rs m41,28941,392 99.7%   
Gross profit Rs m12814,460 0.9%  
Depreciation Rs m1,4891,233 120.8%   
Interest Rs m2,25323 9,967.7%   
Profit before tax Rs m-2,47213,953 -17.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2113,349 -6.3%   
Profit after tax Rs m-2,26010,604 -21.3%  
Gross profit margin %0.335.6 0.9%  
Effective tax rate %8.524.0 35.6%   
Net profit margin %-5.626.1 -21.6%  
BALANCE SHEET DATA
Current assets Rs m46,16040,105 115.1%   
Current liabilities Rs m19,2586,595 292.0%   
Net working cap to sales %67.082.5 81.3%  
Current ratio x2.46.1 39.4%  
Inventory Days Days101119 85.0%  
Debtors Days Days9481 116.6%  
Net fixed assets Rs m40,16519,995 200.9%   
Share capital Rs m553531 104.1%   
"Free" reserves Rs m32,81453,043 61.9%   
Net worth Rs m33,36753,574 62.3%   
Long term debt Rs m31,9030-   
Total assets Rs m89,68761,585 145.6%  
Interest coverage x-0.1618.4 -0.0%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.40.7 67.8%   
Return on assets %017.3 -0.0%  
Return on equity %-6.819.8 -34.2%  
Return on capital %-0.326.1 -1.3%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m9,12135,384 25.8%   
Fx outflow Rs m2,13310,399 20.5%   
Net fx Rs m6,98824,985 28.0%   
CASH FLOW
From Operations Rs m-2,69511,493 -23.4%  
From Investments Rs m-6,863-11,372 60.3%  
From Financial Activity Rs m12,545-93 -13,474.7%  
Net Cashflow Rs m3,01028 10,599.6%  

Share Holding

Indian Promoters % 74.5 52.0 143.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 11.8 19.5%  
FIIs % 7.7 19.0 40.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   67,757 31,796 213.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jun 25, 2018 03:27 PM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS